Top Psychiatrist WARNING: The Dark Side of Antidepressants Nobody Warns You About | Dr Mark Horowitz
This conversation examines antidepressant prescribing, the evidence behind common explanations for depression, medication effects, and the difficulties some people experience when stopping. Dr Mark Horowitz argues that patients should receive clearer information about benefits, risks, alternatives, and withdrawal, while emphasizing that people should not change or stop medication without professional support. His views are contested in some areas, so the discussion is best understood as one perspective in a complex field—not as personal medical advice.
1. Are Antidepressants Being Overprescribed?
Horowitz opens by saying that antidepressants are widely used and that prescribing continues to rise. He cites about 9 million users in England and 45 million in the United States each year, and says roughly one in ten children and teenagers in both countries use them. He argues that this trend reflects, in part, the growing tendency to treat distress as a medical condition.
He points out that difficult experiences—bereavement, divorce, job loss, illness, loneliness, and financial strain—can cause intense sadness and anxiety. In his view, distress can be part of being human, even when it is severe and deserving of support. He cites a long-running study in New Zealand suggesting that around 70% of participants met criteria for depression or anxiety by age 45, and uses this to argue that episodes of distress are common.
Horowitz traces a change in psychiatric language to 1980, when the Diagnostic and Statistical Manual of Mental Disorders (DSM) shifted from terms such as "depressive reaction" to diagnostic labels such as major depressive disorder. He argues that this made emotional responses to life sound more like illnesses such as diabetes or heart disease, encouraging people to seek medical treatments.
"We all become anxious and depressed at points in our lives."
He is not saying that distress is trivial, or that people should be left alone to suffer. Rather, he questions whether every painful emotional state is best understood as a medical disorder—and whether medication should be the default response.
2. The Defeat Depression Campaign and the Chemical-Imbalance Story
The conversation turns to the UK's Defeat Depression campaign, which Horowitz says appeared on billboards, television, and buses during the 1990s and 2000s. Its messages encouraged people to regard depression as a medical illness and to see a doctor. He says that research conducted around the campaign found that some members of the public resisted this framing: they saw low mood as a response to life events and worried that mood-altering drugs could be dependence-forming or difficult to stop.
According to Horowitz, the campaign responded by emphasizing that depression was an illness "like any other" and that antidepressants were easy to stop. He says drug companies helped fund it, and cites a rise in UK antidepressant use from three in every 100 people to 15 in every 100 over the campaign period. His broader argument is that medical messaging and pharmaceutical promotion helped make antidepressants seem like a routine solution.
Horowitz then challenges the familiar claim that depression is caused by low serotonin. He explains that the hypothesis emerged in the 1960s after some drugs appeared to affect mood and also altered serotonin or noradrenaline. The reasoning, he says, was that if a drug that changes a chemical can affect mood, a shortage of that chemical might cause depression. He calls this the "ex juvantibus fallacy": assuming that the opposite of a treatment's effect must be the cause of the problem. His simple comparison is that aspirin can relieve a headache without headaches being caused by a lack of aspirin.
He says the theory became especially widespread when SSRIs—selective serotonin reuptake inhibitors—were marketed in the 1980s and 1990s. Advertising, including a well-known cartoon campaign for Zoloft, linked depression to low serotonin and presented medication as a way to correct it.
Horowitz refers to research reviews that gathered studies measuring serotonin in different ways, including in blood, urine, spinal fluid, genes, and brain tissue. He says the overall results did not show a consistent difference between people with depression and those without it. He also notes that professional organizations have moved away from claiming that depression is caused by low serotonin.
"They might know it, but they forgot to tell the public."
Horowitz's point is not that the brain plays no role in mood. Rather, he questions whether a chemical explanation is the most useful account of why someone is distressed. He argues that stressful events, personal circumstances, support, temperament, and childhood experiences may be more informative than searching for a single chemical cause.
3. Life Circumstances, Depression, and the "Broken Brain" Narrative
When asked what causes depression if not low serotonin, Horowitz emphasizes the relationship between stressful life events and low mood. He lists examples such as divorce, moving, losing a job, illness, or the death of a loved one. He says studies link the number of stressful events someone experiences with their likelihood of becoming depressed, and describes a large difference between people reporting many such events and those reporting none.
He also mentions temperament and genetics: some people are more sensitive to stress, and personality can be shaped by both upbringing and inherited traits. Still, he argues that the main question should often be what is happening in a person's life and what support or practical changes might help.
To illustrate this, he describes how it would be insensitive to respond to someone grieving their mother by focusing only on brain scans or chemical changes. Those changes may occur, he says, but they do not necessarily tell us what help the grieving person needs.
"When life is awful, people feel miserable."
Horowitz objects to the idea that people are "broken" because they feel distressed. He describes a study in which people were given either a chemical explanation for depression or an explanation based on difficult circumstances. As he recounts it, those given the chemical explanation were more pessimistic about recovery and more inclined to want medication, while those given the life-circumstances explanation felt more able to take action and were more optimistic.
His larger concern is that the explanation offered to someone can influence their expectations and sense of agency. If people are told that their brain is defective, they may feel less able to affect their situation; if they are helped to identify problems and sources of support, they may feel more empowered.
4. What the Trial Evidence Says About Antidepressants
Horowitz describes antidepressants as having a small average effect in short-term trials. He says that many studies compare medication with a placebo over approximately six to eight weeks, and cites an average difference of about two points on a 52-point depression scale. He argues that the improvement in the placebo group can reflect several things: natural recovery, the passage of time, regression to the mean, and the hope that treatment may help.
He also raises concerns about how trials are conducted. He says most studies were funded by drug manufacturers and that some participants may guess whether they are receiving the active medication because they notice bodily effects. In research, this is called unblinding. If people know—or believe—they are taking the real drug, their expectations may influence how they report their symptoms.
Horowitz argues that a statistically measurable difference does not necessarily mean a difference doctors or patients would notice in everyday life. He compares a small score change with a diet pill that leads to only a tiny amount of weight loss: a result can be statistically significant without being clinically meaningful.
The discussion also addresses why some people say antidepressants saved their lives. Horowitz says that people in placebo groups can report major improvement too, and that a medication's emotional effects may offer relief during a period of intense distress. He describes this as emotional blunting: the range of feelings may feel compressed, making someone feel less overwhelmed.
"To have something that turns the volume down from a 10 to a 3 can be a great relief."
He also acknowledges the downside. Some people report feeling emotionally flat, unable to cry, less connected to loved ones, or less interested in activities they once enjoyed. He mentions a study in which healthy volunteers who took an SSRI for several weeks reported emotional blunting, which he considers evidence that medication can contribute to the effect—not only the underlying depression.
5. Side Effects, Sexual Function, and Alternatives
Horowitz's account of the possible adverse effects includes emotional blunting, weight gain, nausea, sleep disruption, and difficulties with memory and concentration. He says antidepressants may affect REM and slow-wave sleep, which are involved in sleep and restoration. He also discusses sexual effects, including reduced desire, difficulty maintaining an erection, and difficulty reaching orgasm.
He mentions post-SSRI sexual dysfunction (PSSD)—persistent sexual problems after stopping an SSRI—as a concern for some people. He says estimates and the evidence are uncertain, and that recovery may take time for some while problems may persist for others. These issues, he argues, should be part of a clear discussion before treatment begins.
The host asks about alternatives. Horowitz says that UK treatment guidance lists multiple non-medication approaches, including forms of therapy, exercise, and mindfulness. The host raises diet and refers to the SMILES trial, which examined a modified Mediterranean-style dietary intervention for people with depression. Horowitz agrees that diet may deserve attention but says it is not included in the guidelines he is discussing.
He highlights problem-solving therapy as a practical approach: identify the main problems in someone's life, work out a next step, and return to obstacles as they arise. His broader point is that different people may need different kinds of help, because "depression" can describe distress arising from very different circumstances.
Horowitz also discusses what happens without immediate treatment. He cites studies suggesting that many people improve over time, including a figure of 85% recovering within 12 months without intervention. He does not present this as a reason to abandon people or simply tell them to wait. Instead, he argues that the figure should provide hope and encourage thoughtful support rather than assuming that medication is always necessary.
"Don't just do something, stand there."
He explains this as a caution against rushing into action just to avoid feeling helpless—not a recommendation to leave someone without care. He says support may include therapy, exercise, changes to difficult circumstances, community, and practical help.
The host raises suicide risk and the fear that medication might be the only way through unbearable pain. Horowitz says antidepressants should not be described as reliably suicide-preventing on the basis of trial evidence. He refers to warnings about increased suicidal thoughts or attempts in some younger people and says some people may become agitated. This is a sensitive and contested area; anyone at immediate risk needs prompt professional or emergency support.
6. Horowitz's Experience Taking and Stopping Medication
Horowitz explains that he took antidepressants for 21 years. He began at age 21 while studying medicine, during a period when he felt overwhelmed and unhappy. He says he was prescribed medication after a brief GP appointment and assumed, as many people do, that a chemical problem was being corrected.
While taking the medication, he experienced daytime tiredness and problems with memory and concentration. He received different explanations for these difficulties, including chronic fatigue and narcolepsy, and began to wonder whether the medication played a role. He later moved from Australia to London to study depression and antidepressants.
Near the end of his PhD, he read about withdrawal effects—something he says he had not been taught about in medical or psychiatric training. He found reports of symptoms such as sweating, shaking, headaches, and panic attacks. He also learned about the idea of tolerance: the body adapts to a drug over time, which can affect how someone responds when they reduce or stop it.
He compared medical papers describing withdrawal as mild and brief with accounts from people online who said stopping had taken years and caused serious disruption. Initially, he tried to "split the difference" and taper over four months. When he reached a low dose, he says he experienced severe insomnia, panic on waking, dizziness, and a sense that the world felt unreal, known as derealization. He eventually resumed the medication because the symptoms felt unbearable.
Horowitz distinguishes physical dependence from addiction. In his explanation, physical dependence means the body has adapted to a drug and may react when it is reduced or stopped; addiction usually involves compulsive use and craving. He compares physical dependence with caffeine dependence, where stopping can cause headaches, while emphasizing that antidepressant withdrawal can be much more severe for some people.
"I was back on the drug, not because it was helpful, but because I was trapped on it."
A few years later, Horowitz tried again, this time reducing by very small amounts over a much longer period. He says it took years, but was more tolerable than his first attempt. He also reports that his tiredness and concentration problems largely improved as he came off the medication. He believes people may not recognize gradual side effects because they develop slowly and can be mistaken for other conditions.
7. Why Withdrawal Can Be Misunderstood
Horowitz says that people he encountered online described symptoms that did not match the mild, short-lived withdrawal presented in some professional sources. He argues that patients can be left unsupported when doctors interpret new symptoms after a dose reduction as a return of depression or anxiety rather than possible withdrawal.
He describes a possible cycle: someone reduces medication, develops severe symptoms, is told the symptoms cannot be withdrawal, and is encouraged to restart or increase the medication. Horowitz says this may lead the person to believe they have a permanent condition requiring long-term treatment.
He stresses that withdrawal experiences vary. Some people may have few difficulties; others may experience significant symptoms lasting weeks, months, or longer. He argues that the brain adapts to medication and that recovery from those adaptations may take time. He also says withdrawal can be serious and, in some cases, life-threatening. His comparison with opioids is careful: he says antidepressants and opioids are different drugs, but that physical dependence and withdrawal can be important with both. He does not claim that they are identical.
The interview emphasizes that distressing withdrawal symptoms warrant clinical help, not shame or dismissal. Horowitz's central criticism is that patients need clinicians who will take their accounts seriously and consider withdrawal as one possible explanation.
8. Tapering: Why Small Reductions Matter
Horowitz recommends discussing any medication change with a qualified prescriber. His core advice in the interview is to taper gradually, adjust the pace to the individual, and be especially careful at low doses. He says many antidepressants are available as liquids, which can make smaller reductions possible.
He compares tapering to climbing a mountain. The danger, in his analogy, is not simply the height reached but the speed of ascent. Likewise, he says, reducing medication too quickly may give the body too little time to adapt. If withdrawal symptoms become difficult, he recommends pausing and discussing the plan with a clinician rather than pushing ahead regardless.
He then explains hyperbolic tapering. In simple terms, the relationship between dose and its effect on the brain is not a straight line. At higher doses, a particular reduction may have a relatively small effect; at lower doses, the same-sized reduction may cause a much larger change. This is why reducing by equal numbers of milligrams at each step may become increasingly difficult near the end.
Horowitz illustrates the idea with a hypothetical reduction from 20 mg to 15 mg, then 10 mg, then 5 mg, then zero. He says the final step can produce a much larger change in the brain's drug effect than the earlier steps, even though the milligram reduction looks similar. His alternative is to make smaller and smaller reductions, including at very low doses.
"Come off slowly at a rate you can tolerate and go much slower at the end."
Horowitz gives about 5% of the most recent dose per month as a rule of thumb for many long-term users, while emphasizing that people differ and may need a faster or slower pace. He describes typical patients at his clinic as having used medication for years and says that tapering can take roughly 12 months to three years, with an average of about 18 months in his clinic. These are examples from his practice, not a universal schedule.
The important practical point is that the pace should be personalized with professional guidance. The episode mentions liquids, compounding pharmacies, and other ways of creating smaller doses, but does not provide a do-it-yourself plan. Do not abruptly stop, split, crush, or otherwise alter medication without advice from a qualified clinician or pharmacist.
9. Informed Choice, Young People, and What Should Change
Horowitz says people should be told more clearly about:
- The likely benefits and limitations of medication.
- Possible adverse effects, including sexual and emotional effects.
- The possibility of physical dependence and withdrawal.
- What tapering might involve.
- Non-medication options and what may happen with time and support.
- How long treatment is expected to continue, and when the plan will be reviewed.
He says that, in his experience, many patients are not given a thorough discussion of side effects or withdrawal. He also criticizes the idea that clinicians should avoid mentioning adverse effects because this might discourage treatment. Informed choice, he argues, requires honest discussion of both potential benefits and risks.
He suggests asking a prescriber questions such as: Why might I be feeling this way? What alternatives could I try? How effective is this medication likely to be? What side effects should I watch for? How long might I take it? When would we review or stop it, and how would we taper? He also discusses "wait and see" approaches, citing a study in which some people improved after receiving an explanation of depression and being monitored without immediate medication or therapy. He presents this as one possible approach for some people, not a substitute for care when someone needs urgent help.
The conversation then focuses on children and teenagers. Horowitz says antidepressant evidence in young people is weaker than in adults, and he argues that long-term effects on developing brains are not well understood. He points to concerns about suicidal thoughts and sexual or developmental effects, while acknowledging that some of the evidence he discusses comes from animal research and does not necessarily translate directly to people.
"We are running the largest open-air experiment that we've ever run."
Horowitz uses this phrase to express concern about widespread long-term prescribing when many trials are short. His conclusion is not that every young person should avoid treatment, but that the evidence, risks, and uncertainties deserve careful consideration.
The host and Horowitz also discuss the role of therapy alongside medication, as well as postnatal depression and PMDD. The wider themes are that treatment should be individualized, and that psychological, social, practical, and physical factors may all matter. The conversation does not provide detailed treatment guidance for either postnatal depression or PMDD.
10. Horowitz's Work and Final Reflections
Horowitz says his own withdrawal experience led him to write about safer ways to stop antidepressants. His work contributed to changes in UK prescribing guidance, including greater recognition of gradual, individualized tapering. He co-authored the Maudsley Deprescribing Guidelines and describes clinical services intended to support people who want to reduce or stop medication. The host notes that services and referrals vary, and the episode points viewers toward the resources listed in its description.
In the closing discussion, Horowitz says that living well means finding a life that feels balanced and suits the individual. He emphasizes self-knowledge: people need to discover which circumstances, relationships, work, and routines fit them.
"We don't come with operating manuals."
The conversation's central message is that emotional distress deserves care, but care should not automatically mean medication or rely on a simplistic chemical explanation. Horowitz calls for clearer evidence, fuller informed consent, a wider range of support, and safer, slower tapering when someone chooses to come off medication.
Important: This episode discusses psychiatric medication and withdrawal. Its claims reflect the guest's views and are not a substitute for medical advice. If you take antidepressants, do not reduce, stop, or change your dose without speaking with your prescriber. If you feel at immediate risk of harming yourself, seek urgent local emergency or crisis support.
Need a summary like this?
Get instant summaries with Harvest